In September 2021, the Scott Carter Foundation decided to join Oncoheroes’ quest for new pediatric oncology treatments by investing in the company. After almost three years, coinciding with International Childhood Cancer Day, the foundation announced that it maintained its commitment to Oncoheroes. The Scott Carter Foundation will now provide a grant to support the launch of an international clinical trial to test the efficacy of Oncoheroes’ lead compound, Volasertib, in five different types of pediatric cancer. This clinical trial led by Hopp Children’s Cancer Center Heidelberg (KiTZ) represents a new beacon of hope for children and adolescents who have exhausted their treatment options.
Paula Carter, mom to Scott Carter, the brave 13 year-old who tragically passed away in 1993, after a three-year long battle against osteosarcoma, announced the foundation’s new support to Oncoheroes at the Oncothon event. “The Scott Carter Foundation has been dedicated to supporting pediatric cancer research for thirty years. It has been disheartening to find that some treatment protocols have not changed at all and to note that in the last three decades, only seven drugs have been approved specifically for pediatric cancer. It is incredible to partner with a company solely devoted to developing new treatments for these young patients. We're excited to announce our contribution of additional funds to expedite the launch of the Volasertib trial as soon as possible”, stated Paula.
We are profoundly thankful to the Scott Carter Foundation for their steadfast commitment and unwavering support in our joint endeavor to combat pediatric cancer. Their dedication shines as a guiding light, fueling our determination to explore new frontiers in research and innovation.
